ArticleFrontiers in immunology2025
Global burden and genetic insights of RA and JIA in ages 0-19 years: GBD 2021 and MR analysis.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Study on the Treatment of Rheumatoid Arthritis Using a Novel GelMA-HAMA Dual-Network Hydrogel Microneedle Loaded with MTX-NCs in Combination with Adalimumab.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rheumatoid arthritis (RA) is a chronic autoimmune arthritis that predominantly affects adults, whereas juvenile idiopathic arthritis (JIA) comprises a heterogeneous group of childhood-onset arthritides defined by age at onset, clinical phenotype, and immunological profile. Although RA and JIA are classified as distinct diseases, they share overlapping clinical and immunological features, and the nosological relationship between RA and some JIA subtypes remains debated. The global burden of RA and JIA in young people, and the similarities and differences in their underlying immunogenetic features, remain incompletely understood. Methods: We utilized GBD 2021 data to describe trends in incidence, prevalence, and disability-adjusted life years for RA in individuals aged 0-19 years, as defined within the GBD framework, from 1990 to 2021. In parallel, we performed two-sample Mendelian randomization (MR) using genome-wide association study summary statistics from European-ancestry cohorts to assess associations of genetically proxied levels of 731 immune-cell traits, 91 circulating inflammatory proteins, and 1,400 serum metabolites with RA and JIA risk. Results: From 1990 to 2021, global age-standardized incidence and prevalence of RA in individuals aged 0-19 years increased, whereas disability-adjusted life years declined slightly. The aggregated burden was higher in females and in high-sociodemographic index regions. MR identified overlapping genetically proxied immune-cell and inflammatory protein traits for RA and JIA, including CD28 on CD8 Conclusion: Our study highlights a rising global burden of GBD-defined RA among children and adolescents and delineates shared and distinct patterns of genetically predicted immune-cell, inflammatory protein, and metabolite traits associated with RA and JIA. These observations suggest that immunologically informed approaches could complement existing age- and phenotype-based classifications and help refine early recognition and risk stratification of inflammatory arthritis across the life course.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.